U.S. Markets open in 6 hrs 48 mins

Adaptimmune Therapeutics Third Quarter 2022 Earnings: Beats Expectations

Adaptimmune Therapeutics (NASDAQ:ADAP) Third Quarter 2022 Results

Key Financial Results

  • Revenue: US$7.01m (up 483% from 3Q 2021).

  • Net loss: US$41.4m (loss narrowed by 2.3% from 3Q 2021).

  • US$0.25 loss per share (improved from US$0.27 loss in 3Q 2021).


All figures shown in the chart above are for the trailing 12 month (TTM) period

Adaptimmune Therapeutics Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 40%. Earnings per share (EPS) also surpassed analyst estimates by 83%.

Looking ahead, revenue is forecast to grow 36% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 39% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 4 warning signs for Adaptimmune Therapeutics (1 is significant!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here